Clinical trials: Lymphoproliferative Disorders
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant
This phase II trial studies pentostatin and donor lymphocyte infusion in preventing graft rejection in patients who have undergone donor stem cell transplant.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Trial name
- NCT00096161
- Testing
- Cyclosporine, Mycophenolate Mofetil, Pentostatin
- Where
- 5 sites in United States, Italy
- Volunteers
- 36 people
- Sponsor
- Fred Hutchinson Cancer Center
Refractory Solid Tumors, Lymphoma
A Phase 1 Continuous Intravenous Infusion Study of Terameprocol (EM-1421) in Subjects With Refractory Solid Tumors
This is a Phase I continuous infusion study designed to explore if constant concentration over time adds to the effectiveness of terameprocol without increasing toxicity. It will also explore weekly dosing as an option.
- Trial name
- NCT00664586
- Testing
- Terameprocol (EM-1421)
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Erimos Pharmaceuticals
Lymphangioleiomyomatosis
Pulmonary Rehabilitation in Lymphangioleiomyomatosis
Lymphangioleiomyomatosis (LAM) is a rare disease in which reduced exercise capacity is frequently present. The mechanisms applied are airflow obstruction, abnormal diffusion capacity and dynamic hyperinflation (DH).
- Trial name
- NCT02009241
- Testing
- Pulmonary Rehabilitation
- Where
- Brazil
- Volunteers
- 40 people
- Sponsor
- University of Sao Paulo General Hospital
Diffuse Large B-cell Lymphoma
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
Participants in this study will have diffuse large B-cell lymphoma (DLBCL) that has come back or not gotten better with treatment.
- Trial name
- ECHELON-3 (NCT04404283)
- Testing
- Brentuximab vedotin, Rituximab, Lenalidomide
- Where
- 143 sites in United States, Australia and 12 more
- Volunteers
- 240 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Eosinophilic Asthma, EGPA - Eosinophilic Granulomatosis With Polyangiitis
Prospective Registry of Eosinophilia With Respiratory Manifestations With Translational Research Identifying and Characterizing Eosinophils
Introduction: The etiology and therapy of eosinophilic lung diseases are still poorly understood. For individual forms of disease, such as eosinophilic asthma or eosinophilic granulomatosis with polyangiitis (EGPA), new…
- Conditions
- Eosinophilic Asthma, EGPA - Eosinophilic Granulomatosis With Polyangiitis, Samter Triad, HES - Hypereosinophilic Syndrome
- Trial name
- PROMETHEos (NCT04538937)
- Testing
- no intervention
- Where
- Austria
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Medical University Innsbruck
Mantle Cell Lymphoma
Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy
This is a Phase 2, multicentre, single arm study that evaluates the efficacy and safety of glofitamab in MCL patients with inadequate response or relapse following CAR T-cell therapy.
- Trial name
- NCT07453095
- Testing
- Glofitamab
- Where
- 14 sites in Italy
- Volunteers
- 41 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Leukemia, Acute Lymphoblastic
A Treatment Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
The pilot study collects the experience of previously successful treatment of infants, children and young adults, with ALL from a number of well-renowned study groups into a new platform protocol, which is both a comprehensive…
- Trial name
- NCT03911128
- Testing
- Observational
- Where
- 57 sites in Denmark, Estonia and 6 more
- Volunteers
- 500 people
- Sponsor
- Mats Heyman
Follicular Lymphoma
Immunochemotherapy, Zevalin, and Bone Marrow Transplant for Follicular Lymphoma
Follicular lymphoma has historically been considered an incurable lymphoma. By combining multiple effective treatments, the investigators believe that prolonged disease-free survival is achievable in this disease.
- Trial name
- MasterPlan (NCT01130194)
- Testing
- Combination of treatment modalities
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- St. Louis University
Leukemia, Lymphoma
Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment
RATIONALE: Drugs used in chemotherapy, such as clofarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Leukemia, Lymphoma, Small Intestine Cancer
- Trial name
- NCT00416351
- Testing
- clofarabine
- Where
- 3 sites in United States
- Volunteers
- 29 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia
Pharmacists Coordinated Care Oncology Model (PCOM) for Patients Taking Oral Anti-cancer Medications
The objective of this study is to improve medication, symptom, and disease management of patients with hematological malignancies and multiple chronic conditions (2 or more conditions in addition to cancer) through care…
- Conditions
- Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Multiple Chronic Conditions
- Trial name
- NCT04595851
- Testing
- Patient Reported Outcome Measure (PROM), Comprehensive Medication Review (CMR), Communications between oncology and primary care pharmacists
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Michigan Rogel Cancer Center
Lymphoma
Antibiotic Therapy in Treating Patients With Low Grade Gastric Lymphoma
RATIONALE: Antibiotics may stop the growth of Helicobacter pylori which may be associated with gastric lymphoma. PURPOSE: Phase II trial to study the effectiveness of antibiotic therapy in treating patients with low grade gastric…
- Trial name
- NCT00003151
- Testing
- bismuth subcitrate, amoxicillin, clarithromycin
- Where
- 22 sites in United Kingdom
- Volunteers
- 96 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Advanced Hematologic Malignancies
Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given Twice Weekly for Three Consecutive Weeks in Patients With Advanced Hematologic Malignancies
Chemotherapy resistance is a major cause of death in patients with advanced hematologic malignancies. The proposed novel mechanism of action, non-cross resistance with chemotherapeutic agents currently used in the clinic, and…
- Trial name
- NCT01034475
- Testing
- CPI-613
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Wake Forest University Health Sciences
Lymphoma
Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell or bone marrow transplantation may allow the doctor to give…
- Trial name
- NCT00006373
- Testing
- etoposide, ifosfamide, topotecan hydrochloride
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Sarcoidosis, Endosonography
EBUS vs EUS-B for Diagnosing Sarcoidosis
Rationale: Endosonography with mediastinal/ hilar nodal sampling is the test of choice to diagnose sarcoidosis stage I and II - in case tissue verification of noncaseating granulomas is indicated.
- Trial name
- NCT02540694
- Testing
- Endosonography
- Where
- Netherlands
- Volunteers
- 350 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
AL Amyloidosis
Towards Effective, Patient-tailored Anti-plasma Cell Therapies in AL Amyloidosis: Predicting Drug Response and Overcoming Drug Resistance
Through an observational clinical study, partly prospective and partly retrospective, based on the collection of clinical data and on in vitro experimental analyses carried out on residual biological samples obtained during…
- Trial name
- NCT07585331
- Where
- Italy
- Volunteers
- 250 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Refractory Multiple Myeloma
Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
RATIONALE: Drugs used in chemotherapy, such as bendamustine hydrochloride and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01049945
- Testing
- bendamustine hydrochloride, lenalidomide, dexamethasone
- Where
- 5 sites in United States
- Volunteers
- 70 people
- Sponsor
- Mayo Clinic
Multiple Myeloma, Newly Diagnosed
Low Dose Teclistamab in Newly Diagnosed Multiple Myeloma Patients
This single-arm, open-label study aims to determine the efficacy and safety of low-dose, limited-duration teclistamab as a consolidation scheme in newly diagnosed multiple myeloma (NDMM) patients.
- Trial name
- NCT06758375
- Testing
- Low-dose teclistamab
- Where
- Mexico
- Volunteers
- 10 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma
This phase I/II trial studies the best dose and side effects of venetoclax and how well it works in combination with ixazomib and dexamethasone in treating patients with t(11;14) negative multiple myeloma that has come back or…
- Conditions
- Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma, t(11;14) Negative
- Trial name
- NCT03856112
- Testing
- Dexamethasone, Ixazomib, Ixazomib Citrate
- Sponsor
- National Cancer Institute (NCI)
Lymphoma, Indolent Non-hodgkin Lymphoma
MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma
This is a phase II pilot, single arm, open label study designed to assess the efficacy, safety, and feasibility of MRD adapted duration of BR for untreated or R/R iNHL.
- Trial name
- NCT06557330
- Testing
- Bendamustine, Rituximab
- Volunteers
- 24 people
- Sponsor
- Fox Chase Cancer Center
Diffuse Large B-cell Lymphoma
CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymphoma
Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin's lymphoma, accounting for 35% of lymphoma. Chimeric antigen receptor T cell (CAR-T) therapy is a new method to treat DLBCL.
- Trial name
- CICPD (NCT04381741)
- Testing
- CD19-7×19 CAR-T plus PD1 monoclonal antibody
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine